| Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals JJ Lee, R Wedow, A Okbay, E Kong, O Maghzian, M Zacher, ... Nature genetics 50 (8), 1112-1121, 2018 | 2435* | 2018 |
| Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences R Karlsson Linnér, P Biroli, E Kong, SFW Meddens, R Wedow, ... Nature genetics 51 (2), 245-257, 2019 | 730 | 2019 |
| Disentangling policy effects using proxy data: Which shutdown policies affected unemployment during the COVID-19 pandemic? E Kong, D Prinz Journal of Public Economics 189, 104257, 2020 | 264* | 2020 |
| How do copayment coupons affect branded drug prices and quantities purchased? L Dafny, K Ho, E Kong American Economic Journal: Economic Policy 16 (3), pp. 314–46, 2024 | 19 | 2024 |
| PROMIS computer adaptive tests compared with time to brake in patients with complex lower extremity trauma CY Kim, DH Wiznia, L Averbukh, A Torres, E Kong, S Kim, MP Leslie Journal of orthopaedic trauma 30 (11), 592-596, 2016 | 15 | 2016 |
| Adverse selection and (un) natural monopoly in insurance markets E Kong, T Layton, M Shepard National Bureau of Economic Research, 2024 | 13* | 2024 |
| Provision of hospital price information after increases in financial penalties for failure to comply with a US federal hospital price transparency rule E Kong, Y Ji JAMA Network Open 6 (6), e2320694-e2320694, 2023 | 10 | 2023 |
| US hospital characteristics associated with price transparency regulation compliance Y Ji, E Kong JAMA Health Forum 3 (6), e221702-e221702, 2022 | 10 | 2022 |
| Do physician incentives increase patient medication adherence? E Kong, J Beshears, D Laibson, B Madrian, K Volpp, G Loewenstein, ... Health Services Research 55 (4), 503-511, 2020 | 10 | 2020 |
| Turnover in zero-premium status among health insurance marketplace plans available to low-income enrollees E Kong, M Shepard, A McIntyre JAMA Health Forum 3 (4), e220674-e220674, 2022 | 4 | 2022 |
| Estimating competitive effects in firm entry with applications in the generic pharmaceutical industry E Kong Senior Essay, Yale University, New Haven, CT, 2016 | 3 | 2016 |
| Characterizing the Reaction of Doctors to COVID-19 on Twitter K Hsia, E Kong Journal of quantitative description: digital media 2, 10.51685/jqd. 2022.012, 2022 | 2 | 2022 |
| The Fall and Rise in ACA Insurer Competition: The Role of Reinsurance M Shepard, TJ Layton, E Kong, D Anderson ASHEcon 2024 Conference, 2024 | | 2024 |
| Market Incentives and the Drug Development Pipeline: Evidence from Antibiotics E Kong, O Zhao Available at SSRN 4676384, 2023 | | 2023 |
| Can Incentives for Drug Innovation Work? Evidence from Antibiotics O Zhao, E Kong 2023 Annual Research Meeting, 2023 | | 2023 |
| Silver-Tier ACA Plans Are Unlikely to Remain Zero-Premium across Years, Creating Risk for Coverage Loss E Kong, M Shepard, A McIntyre 2022 Annual Research Meeting, 2022 | | 2022 |
| A repository of polygenic scores A Okbay, D Benjamin, C Burik, D Cesarini, E Kong, O Maghzian, P Turley BEHAVIOR GENETICS 48 (6), 503-503, 2018 | | 2018 |
